Please login to the form below

Not currently logged in
Email:
Password:

kinase inhibitor

This page shows the latest kinase inhibitor news and features for those working in and with pharma, biotech and healthcare.

Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb

Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb

Outside the US, CDK4/6 inhibitor Ibrance was also up by 21%, while sales of tyrosine kinase inhibitor (TKI) Inlyta also increased by 29% globally following increased adoption in the US

Latest news

More from news
Approximately 0 fully matching, plus 187 partially matching documents found.

Latest Intelligence

  • AI: the smart money is on the smart thinking AI: the smart money is on the smart thinking

    Using machine learning, a small team of four researchers were able to identify an initial 370 kinase inhibitors, and then quickly narrow this down to the six most likely to work – ... Using GENTRL, the company was able to design a novel DDR1 kinase

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    Some groups are focusing on SNIPERs – an acronym for Specific and Non-genetic Inhibitor of apoptosis protein-dependent Protein Erasers. – ... These compounds could be used to tackle resistance to kinase inhibitor drugs, for example.

  • Deal Watch January 2018

    The headline value contains significant sales milestones linked to performance of Impact's lead phase III stage asset fedratinib, an oral JAK2 kinase inhibitor in development for the treatment of myelofibrosis ... Acquisition company -  remaining 90%. 9

  • Deal Watch September 2016 Deal Watch September 2016

    No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective

  • Deal Watch June 2016 Deal Watch June 2016

    acquisition assets. 350. CrystalGenomics/ Aptose Biosciences. CG026806 inhibitor of Bruton's tyrosine kinase, FMS-like tyrosine kinase 3 and Aurora kinases (preclinical). † ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe.

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...